BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 16204727)

  • 1. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake.
    Lee JD; Yang WI; Park YN; Kim KS; Choi JS; Yun M; Ko D; Kim TS; Cho AE; Kim HM; Han KH; Im SS; Ahn YH; Choi CW; Park JH
    J Nucl Med; 2005 Oct; 46(10):1753-9. PubMed ID: 16204727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of glucose transporters and hexokinase II in cholangiocellular carcinoma compared using [18F]-2-fluro-2-deoxy-D-glucose positron emission tomography.
    Paudyal B; Oriuchi N; Paudyal P; Higuchi T; Nakajima T; Endo K
    Cancer Sci; 2008 Feb; 99(2):260-6. PubMed ID: 18271924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological presentation of varying 18F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma.
    Paudyal B; Oriuchi N; Paudyal P; Tsushima Y; Higuchi T; Miyakubo M; Ishikita T; Nakajima T; Endo K
    Ann Nucl Med; 2008 Jan; 22(1):83-6. PubMed ID: 18250992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
    Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
    Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between 18-F-fluoro-deoxy-D-glucose uptake and expression of glucose transporter 1 and pyruvate kinase M2 in intrahepatic cholangiocarcinoma.
    Suzuki H; Komuta M; Bolog A; Yokobori T; Wada S; Araki K; Kubo N; Watanabe A; Tsukagoshi M; Kuwano H
    Dig Liver Dis; 2015 Jul; 47(7):590-6. PubMed ID: 25912843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses.
    Ho CL; Yu SC; Yeung DW
    J Nucl Med; 2003 Feb; 44(2):213-21. PubMed ID: 12571212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma.
    Paudyal B; Paudyal P; Oriuchi N; Tsushima Y; Nakajima T; Endo K
    Int J Oncol; 2008 Nov; 33(5):1047-54. PubMed ID: 18949368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in 18F-FDG Uptake and Expression of Glucose Transporter Between 2 Distinct Subtypes of Mass-Forming Intrahepatic Cholangiocarcinomas.
    Kozaka K; Kobayashi S; Takamura H; Sato Y; Kitao A; Inoue D; Yoneda N; Tajima H; Kinuya S; Harada K; Ohta T; Koda W; Matsui O; Gabata T
    Clin Nucl Med; 2020 Jun; 45(6):e267-e273. PubMed ID: 32366791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenic FDG uptake predicts poor prognosis in patients with unresectable cholangiocarcinoma.
    Pak K; Kim SJ; Kim IJ; Kim DU; Kim K; Kim H; Kim SJ
    Nuklearmedizin; 2014; 53(2):26-31. PubMed ID: 24305850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the role of hexokinase type II in cellular proliferation and apoptosis using human hepatocellular carcinoma cell lines.
    Ahn KJ; Hwang HS; Park JH; Bang SH; Kang WJ; Yun M; Lee JD
    J Nucl Med; 2009 Sep; 50(9):1525-32. PubMed ID: 19690031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas.
    Moon CM; Bang S; Chung JB; Park SW; Song SY; Yun M; Lee JD
    J Gastroenterol Hepatol; 2008 May; 23(5):759-65. PubMed ID: 17931372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of acetyl coenzyme A synthetase for 11C-acetate uptake and cell survival in hepatocellular carcinoma.
    Yun M; Bang SH; Kim JW; Park JY; Kim KS; Lee JD
    J Nucl Med; 2009 Aug; 50(8):1222-8. PubMed ID: 19617323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
    Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein expression affects 18F-fluorodeoxyglucose accumulation in hepatocellular carcinoma in vivo and in vitro.
    Seo S; Hatano E; Higashi T; Nakajima A; Nakamoto Y; Tada M; Tamaki N; Iwaisako K; Kitamura K; Ikai I; Uemoto S
    Int J Oncol; 2009 May; 34(5):1303-12. PubMed ID: 19360342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in total lesion glycolysis and clinical outcome after (90)Y radioembolization in intrahepatic cholangiocarcinoma.
    Filippi L; Pelle G; Cianni R; Scopinaro F; Bagni O
    Nucl Med Biol; 2015 Jan; 42(1):59-64. PubMed ID: 25213104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictability of preoperative 18F-FDG PET for histopathological differentiation and early recurrence of primary malignant intrahepatic tumors.
    Song JY; Lee YN; Kim YS; Kim SG; Jin SJ; Park JM; Choi GS; Chung JC; Lee MH; Cho YH; Choi MH; Kim DC; Choi HJ; Moon JH; Lee SH; Jeong SW; Jang JY; Kim HS; Kim BS
    Nucl Med Commun; 2015 Apr; 36(4):319-27. PubMed ID: 25564069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor.
    Zhao S; Kuge Y; Mochizuki T; Takahashi T; Nakada K; Sato M; Takei T; Tamaki N
    J Nucl Med; 2005 Apr; 46(4):675-82. PubMed ID: 15809491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of (18)F-FDG PET in the management of hepatobiliary and pancreatic tumors.
    De Gaetano AM; Rufini V; Castaldi P; Gatto AM; Filograna L; Giordano A; Bonomo L
    Abdom Imaging; 2012 Dec; 37(6):983-1003. PubMed ID: 22527152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic Analysis of Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Distinguishing Hepatocellular Carcinoma From Cholangiocarcinoma in Pre-Liver Transplantation Evaluation.
    Lin CC; Cheng YF; Chiang HJ; Lazo M; Chang CD; Tsang LL; Yu CY; Hsu HW; Chen WT; Wang CC; Liang JL; Eng HL; Chen CL; Ou HY
    Transplant Proc; 2016 May; 48(4):1041-4. PubMed ID: 27320551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of [(18)F]-fluoroacetate PET/CT as a tumor-imaging modality: preclinical study in healthy volunteers and clinical evaluation in patients with liver tumor.
    Takemoto K; Hatano E; Nishii R; Kagawa S; Kishibe Y; Takahashi M; Yamauchi H; Matsumura K; Zaima M; Toriguchi K; Tanabe K; Kitamura K; Seo S; Taura K; Endo K; Uemoto S; Higashi T
    Ann Nucl Med; 2014 May; 28(4):371-80. PubMed ID: 24599824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.